Brooke E. Hickey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Brooke E. Hickey has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Christine A. Pratilas
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA
34 shared publications - Marisa D. Ciesielski
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
34 shared publications - Melissa L. Fishel
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
34 shared publications - Silpa Gampala
Department of Pediatrics, Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis IN, USA; Indiana University Simon Comprehensive Cancer Center, Indianapolis IN, USA
34 shared publications - Steven D. Rhodes
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
34 shared publications - Steven Patrick Angus
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
34 shared publications
Latest Publications
- Open Access
ZNF423 depletion induces the integrated stress response and represents a potential vulnerability in NF1-associated MPNST
Malignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas with limited systemic therapies and represent the leading cause of mortality for individuals with neurofibromatosis type 1 (NF1). Malignant progression can reactivate developmental precursor programs that are largely absent from normal nerve and benign tumors, creating tumor-selective vulnerabilities. Zinc finger protein 423 (ZNF423; also known as OAZ/ROAZ) is a developmentally regulated transcription factor that delays olfactory precursor differentiation and has been implicated in B-cell malignancy. Here, we asked whether ZNF423 is reactivated and functionally required in NF1-associated MPNST. In genetically defined models, Nf1 loss reduced Zfp423 in a benign tumor cell-of-origin context, whereas combined Nf1 and Cdkn2a loss induced marked Zfp423 upregulation during transformation. ZNF423 depletion impaired DNA synthesis and proliferation, induced DNA damage signaling, and activated the integrated stress response (ISR), increasing sensitivity to cytotoxic agents. In an orthotopic MPNST model, shRNA-mediated suppression of ZNF423 reduced tumor initiation in vivo; however, tumors that eventually emerged showed restoration of ZNF423 expression. ZNF423 is developmentally restricted in the peripheral nerve lineage yet elevated in MPNST, with single-cell analyses of patient nerve sheath tumors revealing localized expression restricted to malignant cells rather than SOX10-positive benign tumor cells. These data identify ZNF423 as a putative malignant biomarker, a potential dependency in NF1-MPNST, and nominate downstream stress and genome maintenance pathways as cooperative therapeutic vulnerabilities. STATEMENT OF SIGNIFICANCE: ZNF423 is a developmentally restricted transcription factor selectively reactivated in NF1-associated malignant peripheral nerve sheath tumors. Targeted ablation triggers the integrated stress response, impairs DNA synthesis, sensitizes cells to chemotherapy and PARP inhibition, and restricts in vivo growth. ZNF423 represents a candidate biomarker and therapeutic vulnerability in this aggressive sarcoma.
Open AccessZNF423 depletion induces the integrated stress response and represents a potential vulnerability in NF1-associated MPNST
Malignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas with limited systemic therapies and represent the leading cause of mortality for individuals with neurofibromatosis type 1 (NF1). Malignant progression can reactivate developmental precursor programs that are largely absent from normal nerve and benign tumors, creating tumor-selective vulnerabilities. Zinc finger protein 423 (ZNF423; also known as OAZ/ROAZ) is a developmentally regulated transcription factor that delays olfactory precursor differentiation and has been implicated in B-cell malignancy. Here, we asked whether ZNF423 is reactivated and functionally required in NF1-associated MPNST. In genetically defined models, Nf1 loss reduced Zfp423 in a benign tumor cell-of-origin context, whereas combined Nf1 and Cdkn2a loss induced marked Zfp423 upregulation during transformation. ZNF423 depletion impaired DNA synthesis and proliferation, induced DNA damage signaling, and activated the integrated stress response (ISR), increasing sensitivity to cytotoxic agents. In an orthotopic MPNST model, shRNA-mediated suppression of ZNF423 reduced tumor initiation in vivo; however, tumors that eventually emerged showed restoration of ZNF423 expression. ZNF423 is developmentally restricted in the peripheral nerve lineage yet elevated in MPNST, with single-cell analyses of patient nerve sheath tumors revealing localized expression restricted to malignant cells rather than SOX10-positive benign tumor cells. These data identify ZNF423 as a putative malignant biomarker, a potential dependency in NF1-MPNST, and nominate downstream stress and genome maintenance pathways as cooperative therapeutic vulnerabilities. STATEMENT OF SIGNIFICANCE: ZNF423 is a developmentally restricted transcription factor selectively reactivated in NF1-associated malignant peripheral nerve sheath tumors. Targeted ablation triggers the integrated stress response, impairs DNA synthesis, sensitizes cells to chemotherapy and PARP inhibition, and restricts in vivo growth. ZNF423 represents a candidate biomarker and therapeutic vulnerability in this aggressive sarcoma.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S19 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
GOBP spatially profiled ANNUBP downregulated genes
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S19 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
GOBP spatially profiled ANNUBP downregulated genes
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
Upregulated protein coding genes from the GSE178989 dataset
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
Upregulated protein coding genes from the GSE178989 dataset
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
Sciatic Nerve Atlas DLK1 Analysis
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
Sciatic Nerve Atlas DLK1 Analysis
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S15 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
TCGA GOBP 2023 Downregulated genes
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S15 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
TCGA GOBP 2023 Downregulated genes
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S12 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
Supplementary Table S12 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S12 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
Supplementary Table S12 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
Supplementary Table S4 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
Supplementary Table S4 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S14 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
Supplementary Table S14 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S14 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
Supplementary Table S14 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
Immunologic profiling of DLK1Hi compared to DLK1Lo MPNST from the TCGA and GSE178989 datasets
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures
Immunologic profiling of DLK1Hi compared to DLK1Lo MPNST from the TCGA and GSE178989 datasets